Department of Health and Social Care

We have taken ‘non-UK residents’ to mean chargeable overseas visitors. The Department publishes data on the income identified from chargeable overseas visitors in England as part of the Department of Health and Social Care Annual Report and Accounts. The cash payments received by the National Health Service from overseas visitors are also published annually in the consolidated NHS provider accounts. The information for the last three years is available at the following links:

https://assets.publishing.service.gov.uk/media/6745b836e7cf64050b8098c4/consolidated-nhs-provider-accounts_annual-report-and-accounts-2023-to-2024_print-ready.pdf (page 79)

https://assets.publishing.service.gov.uk/media/676150ef26a2d1ff18253415/dhsc-annual-report-and-accounts-2023-2024-web-accessible.pdf (page 284)

https://assets.publishing.service.gov.uk/media/65b2a4fc5f8ce2000d3ae544/consolidated-provider-accounts-2022-to-2023-print.pdf (page 74)

https://assets.publishing.service.gov.uk/media/65b236c81702b10013cb1289/DHSC-Annual-report-and-accounts-2022-2023-web-accessible.pdf (page 275)

https://www.england.nhs.uk/wp-content/uploads/2023/01/consolidated-provider-accounts-21-22-final.pdf (page 66)

https://assets.publishing.service.gov.uk/media/63e50dc0d3bf7f05c8e947a8/dhsc-annual-report-and-accounts-2021-2022_web-accessible.pdf (page 319)

NHS charges can be recovered up to six years from the date of invoice, and therefore the amount recovered in a year does not necessarily mean it was identified in the same financial year.

Guidance on the use of medical devices is a matter for the National Institute for Health and Care Excellence, which has existing guidance on the use of left ventricular assistance devices available at the following link:

https://www.nice.org.uk/guidance/ipg516

The requested data is not held centrally in a reportable format.

All frontline health care workers should be offered a flu vaccination by their employer, with this year’s campaign starting from 1 October 2025 and remaining until 31 March 2026. In the NHS England Urgent and Emergency Care Plan 2025/26, which was published in June 2025, a commitment was given to improve vaccination rates for frontline staff towards the pre-pandemic uptake level of 2018/19, and included the aim to improve uptake by at least 5% in 2025/26.

The UK Health Security Agency publishes monthly provisional vaccine uptake data for frontline healthcare workers from November to March. The first monthly data for this season was published on 27 November 2025 and includes all vaccinations given between 1 September and 31 October 2025.

The Department works closely with the UK Health Security Agency and NHS England to encourage everyone who is eligible to get their flu vaccine. For 2025/26, there is an enhanced communications campaign using multiple ways to reach staff including workplace communications, partnerships with unions and professional bodies, and materials tailored for different healthcare roles. All National Health Service trusts have been asked to have an accessible occupational health vaccination offer to staff throughout the entire flu campaign, including onsite bookable and walk-in appointments. Additionally, a range of digital services have been put in place, including to support individuals to make informed choices about when and where to receive the vaccinations.

NHS England has also developed bespoke data reports to monitor trust uptake in real time, working closely with NHS regions and trusts to determine influencing factors for staff uptake and promoting cross-system working to share best practice throughout the seasonal campaign.

The Quality and Outcomes Framework indicator relating to the learning disability register was retired for the 2025/26 contract year.

National published data is recorded on a financial year basis from April to March. This published data shows that, at the end of October 2025, there were 342,928 people aged 14 years old and over on a general practice learning disability register. This is approximately a quarter of the estimated number of adults with a learning disability in England.

At the Autumn Budget, we announced our commitment to deliver 250 Neighbourhood Health Centres (NHCs) through the NHS Neighbourhood Rebuild Programme. This will deliver NHCs through a mixture of refurbishments to expand and improve sites over the next three years and new-build sites opening in the medium term. The first 120 NHCs are due to be operational by 2030 and will be delivered through public private partnerships and public capital.

Nationwide coverage will take time, but we will start in the areas of greatest need where healthy life expectancy is lowest, including rural towns and communities with higher deprivation levels, targeting places where healthy life expectancy is lowest and delivering healthcare closer to home for those that need it the most.

Integrated care boards will be responsible for determining the most appropriate locations for NHCs.

We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations, including the workforce. While the focus on personalised, coordinated care will be consistent, that will mean the service will look different in rural communities, coastal towns, or deprived inner cities. A 10 Year Workforce Plan will be published in spring 2026, which will set out action to create a workforce to deliver the 10-Year Health Plan.

The Government and Prostate Cancer UK (PCUK) have partnered together on the £42 million TRANSFORM screening trial to find the best way to screen men for prostate cancer, to find it before it becomes advanced and harder to treat. PCUK is leading the development of the trial, with the Government contributing £16 million through the National Institute for Health and Care Research.

The TRANSFORM trial will aim to address some of the inequalities that exist in prostate cancer diagnosis. For example, one in four black men will develop prostate cancer, double the risk of other men, and often at a younger age. The trial will ensure that at least 10% of the men who are invited to participate in the trial are black.

The UK National Screening Committee (UK NSC), that advises ministers in all four nations of the United Kingdom, has carried out an evidence review to look at screening for prostate cancer. It is only where the UK NSC is confident that screening provides more good than harm that a screening programme is recommended.

On 28 November 2025, the UK NSC opened a 12- week public consultation on a draft recommendation to:

• offer a targeted national prostate cancer screening programme to men with confirmed BRCA1/2 gene variants every two years from 45 years old to age 61 years old;
• not recommend population screening;
• not recommend targeted screening of black men;
• not recommend targeted screening of men with family history; and
• collaborate with the Transform trial team to answer outstanding questions on screening effectiveness for black men and men with a family history as soon as the trial data becomes available, and to await the results of the study to develop and trial a more accurate test than the prostate specific antigen test alone, to improve the balance of benefit and harm of screening.

After the consultation closes, in early 2026, the UK NSC will make a final recommendation on screening for prostate cancer. Ministers will consider whether to accept the recommendation at this time.

The Government had two contracts with Palantir Technologies UK which have expired. The first, worth £908,333.33, was for Foundry Software and implementation, between 12 June 2020 and 30 September 2020. The second, worth £750,000, was for the Adult Social Care Data Analytics Project, an extension of Palantir Foundry, between 12 October 2021 and 11 January 2022. There are no contracts in the process of being agreed.

Everyone who has drug and/or alcohol treatment needs is assessed in prison and offered a referral to a treatment or recovery service on release. The Department works closely with national partners and with local authorities to improve continuity of care between prison and community drug and alcohol treatment systems. To support this, the Department has published a continuity of care self-assessment toolkit, and shares actionable data and good practice with drug and alcohol partnerships on a regular basis. The continuity of care self-assessment toolkit is available at the following link:

https://www.gov.uk/government/publications/continuity-of-care-from-prison-to-community-self-assessment-tool

This work has enabled more people than ever to receive the treatment they need following their release from prison. The proportion of adults released from prison and successfully starting community treatment within three weeks of release was 53% in 2023 to 2024. This is a 10% increase from the proportion reported in 2022 to 2023, at 43%, and is 23% higher than when this data was first reported in 2015 to 2016, at 30%.

It has been illegal for businesses to sell or supply single-use vapes since 1 June 2025. The Government is investing £10 million of new funding in Trading Standards in 2025/26, to support the enforcement of illicit and underage tobacco and vape sales. As part of this package, we have provided training to over 760 Trading Standards officers on the single-use vapes ban, ensuring they have a strong understanding of the regulations and are confident in enforcing them.

Through this programme, we are also funding the Vaping Expert Panel, which provides guidance to Trading Standards officers on vaping products to support the consistent enforcement of regulations. The panel has published 20 pieces of guidance, and Trading Standards officers are able to contact the panel if they would like further clarification or advice.

On 19 November 2025, to coincide with International Men’s Health Day, we published the first ever Men’s Health Strategy for England. The strategy includes tangible actions to improve access to healthcare, provide the right support to enable men to make healthier choices, develop healthy living and working conditions, foster strong social, community, and family networks, and address societal norms. It also considers how to prevent and tackle the biggest health problems affecting men of all ages, which include mental health and suicide prevention, respiratory illness, prostate cancer, and heart disease.

We are taking a range of actions to improve men’s health literacy. For example, our landmark partnership with the Premier League will bring together football clubs and the Government to improve health literacy, particularly around mental health and suicide prevention. We are also ensuring health literacy improvements are embedded at the community level, building the evidence base on heath literacy in men, and identifying ways to build media literacy skills in men to help them critically assess health information and protect against misinformation that harms health.

We will consider the impacts on young men in the implementation of the strategy. The strategy sets up a strong foundation for improving how we think and act on men's health and we will learn, iterate, and adapt as new challenges emerge. As a first step, we will work with the Men's Health Academic Network and the voluntary, community, and social enterprise sector to develop and publish a one-year-on report, highlighting the improvements made and where future efforts will need to be targeted.

The Nursery Milk Scheme is a statutory scheme which allows registered early years childcare settings to claim one-third of a pint of milk for all children under the age of five years old who attend the setting for at least two hours per day. The statutory nature of the scheme means that it is not impacted by annual funding discussions, and these discussions therefore have no impact on the childcare settings who use the scheme, or on the suppliers who supply them.

NHS England has published a RightCare toolkit which sets out what good quality diabetes care looks like for children and young adults and which includes guidance on timely and accurate diagnosis.

The National Institute for Health and Care Excellence has published clinical guidelines for the diagnosis, treatment, and care of children and young people with type 1 diabetes.

Through our National Institute for Health and Care Research, we have supported the establishment of the Early Surveillance for Autoimmune diabetes, or the “ELSA” study. This study is exploring the feasibility and benefits of screening for type 1 diabetes.

NHS England runs training sessions on first aid, cardiopulmonary resuscitation (CPR), and the use of defibrillators both in the community and in schools, under the Restart a Heart programme. This training should help to increase confidence in performing CPR on women. NHS England has trained over 35,800 adults and children in CPR and defibrillation in the last 13 years, and 2,134 this year so far. NHS England delivers the sessions via their resuscitation team and via their community first responders.

The Government is committed to tackling the appalling crimes of rape and sexual assault. NHS England has introduced a comprehensive package of measures to improve sexual safety across the National Health Service. NHS England has made tackling sexual misconduct in the NHS a priority, with all trusts and integrated care boards (ICBs) now signed up to the Sexual Safety Charter for the NHS.

NHS England is investing in improving the collection and analysis of sexual violence data to support organisations to implement policies that reduce incidents of sexual misconduct in the NHS. NHS providers have a mandatory duty to notify the Care Quality Commission (CQC) of all incidents that affect the health, safety, and welfare of people who use services, including allegations of sexual assault. The provider must also notify the police if a crime has been committed. The CQC uses the information to monitor the safety of services and to ensure that providers have dealt with incidents appropriately. The CQC publishes reports about the services they inspect on their website.

Data relating to sexual assault in NHS hospitals is currently held at NHS trust level. Local police forces hold data where there has been a report to the police of sexual assault. For assaults on NHS staff, the NHS Staff Survey now includes questions about staff experiences of sexual misconduct. Results from the 2024 staff survey show 3.66% experienced unwanted behaviour of a sexual nature from colleagues.

The Department recognises the complex needs of people living with overlapping conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), long COVID, Ehlers-Danlos syndrome, hypermobility spectrum disorders, postural tachycardia syndrome, and mast cell activation syndrome. Our approach focuses on improving care coordination and access to appropriate services.

For ME/CFS, we have published a cross-government final delivery plan, which sets out actions to boost research, improve professional education, and enhance support for daily living, including community-based services and better benefit assessments. While the plan is specific to ME/CFS, it acknowledges overlaps with other complex, multi-system disorders and commits to exploring synergies during implementation.

Additionally, the 10-Year Health Plan aims to transform services and outcomes for people living with complex conditions by prioritising integrated, personalised care. The plan focuses on earlier diagnosis and promotes multidisciplinary teams and community-based services to deliver coordinated support closer to home, reducing reliance on hospital care. Digital innovations, including remote monitoring and personalised care planning, will help manage long-term conditions more effectively. The Plan also commits to 95% of people with complex needs to have a personalised care plan by 2027. Personalised care plans will improve support for people with complex needs by ensuring that care is tailored to the individual and coordinated across services.

In addition, research funded by the National Institute for Health and Care Research into post-viral syndromes and autonomic disorders will help improve understanding autonomic dysfunction and overlapping conditions, accelerate innovation and deliver evidence-based care for patients with complex, multi-system health needs.

No assessment has yet been made as the registration scheme is still in the early stages of policy development. On 8 October 2025, we published a call for evidence on a number of topics related to tobacco, vaping and nicotine products, including the proposal to introduce a new product registration scheme.

However, given the nature of vaping products, which are not healthcare products, officials from the Department and the Office for Product Safety and Standards (OPSS) are considering whether OPSS would be better placed to oversee the future register. The Department and the Medicines and Healthcare products Regulatory Agency will continue to be responsible for the current notification systems until further notice.

Powers in the bill will allow us to charge a fee for the ongoing and continuous registration of products. Exact details on fees, as well as the future registration scheme, will be subject to future consultation.

We recognise that doctors can find it challenging to diagnose Ehlers-Danlos syndrome (EDS) because of the wide range and variability of symptoms, and that the most common type, hypermobile EDS, currently has no specific genetic test.

Resources such as the Royal College of General Practitioners’ EDS Toolkit, now maintained by Ehlers-Danlos Support UK, are helping general practitioners (GPs) to better recognise, respond to, and manage EDS and hypermobility spectrum disorders (HSD) in primary care. For rarer genetically confirmed types of EDS, NHS England commissions a national diagnostic service for EDS.

A primary goal of the national diagnostic service is to educate referring doctors about the diagnosis, investigation, and management of patients with complex and atypical forms of EDS. While the service focuses on rare types and accepts referrals from secondary and tertiary care, its development of guidelines and educational initiatives also benefit GPs who are on the front line of patient care.

Through the 10-Year Health Plan, we are introducing neighbourhood health centres, and deploying multidisciplinary teams to provide holistic support to people with EDS. Patients will benefit from enhanced NHS App functionality, including My Medicines and My Health, and will be able to self-refer to specialist services where appropriate.

Additionally, the 10-Year Health Plan’s commitments on artificial intelligence will give clinicians advanced tools for faster diagnosis, predictive analytics, and personalised care planning. For people with long-term conditions like EDS, this means earlier interventions, better monitoring of complex needs, and more time for clinicians to focus on patient-centred care rather than administrative tasks. The plan also commits to 95% of people with complex needs to have a personalised care plan by 2027.

The Government will publish the 10 Year Workforce Plan in spring 2026. It will set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. By setting out how we will train and provide the staff, technology, and infrastructure the NHS needs, the 10 Year Workforce Plan will ensure that services are more accessible, proactive, and tailored for all patients, including those with EDS.

We recognise that doctors can find it challenging to diagnose Ehlers-Danlos syndrome (EDS) because of the wide range and variability of symptoms, and that the most common type, hypermobile EDS, currently has no specific genetic test.

Resources such as the Royal College of General Practitioners’ EDS Toolkit, now maintained by Ehlers-Danlos Support UK, are helping general practitioners (GPs) to better recognise, respond to, and manage EDS and hypermobility spectrum disorders (HSD) in primary care. For rarer genetically confirmed types of EDS, NHS England commissions a national diagnostic service for EDS.

A primary goal of the national diagnostic service is to educate referring doctors about the diagnosis, investigation, and management of patients with complex and atypical forms of EDS. While the service focuses on rare types and accepts referrals from secondary and tertiary care, its development of guidelines and educational initiatives also benefit GPs who are on the front line of patient care.

Through the 10-Year Health Plan, we are introducing neighbourhood health centres, and deploying multidisciplinary teams to provide holistic support to people with EDS. Patients will benefit from enhanced NHS App functionality, including My Medicines and My Health, and will be able to self-refer to specialist services where appropriate.

Additionally, the 10-Year Health Plan’s commitments on artificial intelligence will give clinicians advanced tools for faster diagnosis, predictive analytics, and personalised care planning. For people with long-term conditions like EDS, this means earlier interventions, better monitoring of complex needs, and more time for clinicians to focus on patient-centred care rather than administrative tasks. The plan also commits to 95% of people with complex needs to have a personalised care plan by 2027.

The Government will publish the 10 Year Workforce Plan in spring 2026. It will set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. By setting out how we will train and provide the staff, technology, and infrastructure the NHS needs, the 10 Year Workforce Plan will ensure that services are more accessible, proactive, and tailored for all patients, including those with EDS.

We recognise that doctors can find it challenging to diagnose Ehlers-Danlos syndrome (EDS) because of the wide range and variability of symptoms, and that the most common type, hypermobile EDS, currently has no specific genetic test.

Resources such as the Royal College of General Practitioners’ EDS Toolkit, now maintained by Ehlers-Danlos Support UK, are helping general practitioners (GPs) to better recognise, respond to, and manage EDS and hypermobility spectrum disorders (HSD) in primary care. For rarer genetically confirmed types of EDS, NHS England commissions a national diagnostic service for EDS.

A primary goal of the national diagnostic service is to educate referring doctors about the diagnosis, investigation, and management of patients with complex and atypical forms of EDS. While the service focuses on rare types and accepts referrals from secondary and tertiary care, its development of guidelines and educational initiatives also benefit GPs who are on the front line of patient care.

Through the 10-Year Health Plan, we are introducing neighbourhood health centres, and deploying multidisciplinary teams to provide holistic support to people with EDS. Patients will benefit from enhanced NHS App functionality, including My Medicines and My Health, and will be able to self-refer to specialist services where appropriate.

Additionally, the 10-Year Health Plan’s commitments on artificial intelligence will give clinicians advanced tools for faster diagnosis, predictive analytics, and personalised care planning. For people with long-term conditions like EDS, this means earlier interventions, better monitoring of complex needs, and more time for clinicians to focus on patient-centred care rather than administrative tasks. The plan also commits to 95% of people with complex needs to have a personalised care plan by 2027.

The Government will publish the 10 Year Workforce Plan in spring 2026. It will set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. By setting out how we will train and provide the staff, technology, and infrastructure the NHS needs, the 10 Year Workforce Plan will ensure that services are more accessible, proactive, and tailored for all patients, including those with EDS.

Powers in the Tobacco and Vapes Bill allow us to establish a new product registration scheme for tobacco, vaping, and nicotine products. On 8 October 2025, we published a call for evidence on a number of topics related to tobacco, vaping, and nicotine products. This includes the proposal to introduce a new product registration scheme.

In the call for evidence, we are seeking information on how best to implement the registration scheme. The evidence gathered will inform development of policy and a subsequent consultation next year.

Powers in the Tobacco and Vapes Bill allow us to establish a new product registration scheme for tobacco, vaping, and nicotine products, including testing requirements.

On 8 October 2025, we published a call for evidence on a number of topics related to tobacco, vaping, and nicotine products, including the proposal to introduce a new product registration scheme. The evidence gathered will inform development of policy and a subsequent consultation next year.

Any new testing requirements introduced following consultation will apply to products produced in the United Kingdom and those imported into the UK.

Reducing the number of lives lost to cancer in England, including ovarian cancer, is a key aim of the National Cancer Plan which will be published in the new year. The plan will set out in further detail how the Government will improve outcomes for cancer patients, including ovarian cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.

The Government knows that many ovarian cancer patients are still left waiting too long for a diagnosis and treatment and so will push to get the National Health Service diagnosing and treating it faster, so that more patients survive the disease and have an improved experience across the system. The Elective Reform Plan, published in January 2025, sets out the productivity and modernisation efforts needed to return to the 18-week constitutional standard by the end of this Parliament. The plan commits to transforming and expanding diagnostic services and speeding up waiting times for tests, a crucial part of reducing overall waiting times and returning to the referral to treatment 18-week standard. This includes expanding existing community diagnostic centres (CDCs), as well as building up to five new ones in 2025/26, to support the NHS to return to meeting the elective waiting time constitutional standard. The plan also commits to CDCs opening 12 hours per day, seven days a week, delivering more same-day tests and consultations and an expanded range of tests, many of which can support the diagnosis of gynaecological cancers, including ovarian cancer.

To support early diagnosis, NHS England is taking a wide range of activity to increase awareness of ovarian cancer. NHS England relaunched the Help Us Help You cancer campaign on the 8 January 2024, to encourage people to get in touch with their general practitioner if they notice, or are worried about, symptoms that could be cancer. Previous phases of the campaign have focused on abdominal symptoms which, among other abdominal cancers, can be indicative of ovarian cancer. NHS England and other NHS organisations, nationally and locally, publish information on the signs and symptoms of many different types of cancer, including ovarian cancer. This information can be found at sources including the NHS website, which is available at the following link:

https://www.nhs.uk/

Reducing the number of lives lost to cancer in England, including ovarian cancer, is a key aim of the National Cancer Plan which will be published in the new year. The plan will set out in further detail how the Government will improve outcomes for cancer patients, including ovarian cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.

The Government knows that many ovarian cancer patients are still left waiting too long for a diagnosis and treatment and so will push to get the National Health Service diagnosing and treating it faster, so that more patients survive the disease and have an improved experience across the system. The Elective Reform Plan, published in January 2025, sets out the productivity and modernisation efforts needed to return to the 18-week constitutional standard by the end of this Parliament. The plan commits to transforming and expanding diagnostic services and speeding up waiting times for tests, a crucial part of reducing overall waiting times and returning to the referral to treatment 18-week standard. This includes expanding existing community diagnostic centres (CDCs), as well as building up to five new ones in 2025/26, to support the NHS to return to meeting the elective waiting time constitutional standard. The plan also commits to CDCs opening 12 hours per day, seven days a week, delivering more same-day tests and consultations and an expanded range of tests, many of which can support the diagnosis of gynaecological cancers, including ovarian cancer.

To support early diagnosis, NHS England is taking a wide range of activity to increase awareness of ovarian cancer. NHS England relaunched the Help Us Help You cancer campaign on the 8 January 2024, to encourage people to get in touch with their general practitioner if they notice, or are worried about, symptoms that could be cancer. Previous phases of the campaign have focused on abdominal symptoms which, among other abdominal cancers, can be indicative of ovarian cancer. NHS England and other NHS organisations, nationally and locally, publish information on the signs and symptoms of many different types of cancer, including ovarian cancer. This information can be found at sources including the NHS website, which is available at the following link:

https://www.nhs.uk/

Reducing the number of lives lost to cancer in England, including ovarian cancer, is a key aim of the National Cancer Plan which will be published in the new year. The plan will set out in further detail how the Government will improve outcomes for cancer patients, including ovarian cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.

The Government knows that many ovarian cancer patients are still left waiting too long for a diagnosis and treatment and so will push to get the National Health Service diagnosing and treating it faster, so that more patients survive the disease and have an improved experience across the system. The Elective Reform Plan, published in January 2025, sets out the productivity and modernisation efforts needed to return to the 18-week constitutional standard by the end of this Parliament. The plan commits to transforming and expanding diagnostic services and speeding up waiting times for tests, a crucial part of reducing overall waiting times and returning to the referral to treatment 18-week standard. This includes expanding existing community diagnostic centres (CDCs), as well as building up to five new ones in 2025/26, to support the NHS to return to meeting the elective waiting time constitutional standard. The plan also commits to CDCs opening 12 hours per day, seven days a week, delivering more same-day tests and consultations and an expanded range of tests, many of which can support the diagnosis of gynaecological cancers, including ovarian cancer.

To support early diagnosis, NHS England is taking a wide range of activity to increase awareness of ovarian cancer. NHS England relaunched the Help Us Help You cancer campaign on the 8 January 2024, to encourage people to get in touch with their general practitioner if they notice, or are worried about, symptoms that could be cancer. Previous phases of the campaign have focused on abdominal symptoms which, among other abdominal cancers, can be indicative of ovarian cancer. NHS England and other NHS organisations, nationally and locally, publish information on the signs and symptoms of many different types of cancer, including ovarian cancer. This information can be found at sources including the NHS website, which is available at the following link:

https://www.nhs.uk/

I refer the Hon. Member to the answer I gave on 9 December 2025 to Question 95574.

I refer the Hon. Member to the answer I gave on 9 December 2025 to Question 95574.

Integrated care boards (ICBs) are responsible for commissioning primary and secondary eye care services to meet local need. We are not aware of any issues with the availability of sight testing services. The decision to commission enhanced eye care services will be determined by local ICBs following a local needs assessment.

Integrated care boards are responsible for assessing the needs of their population and ensuring that the relevant dental services are available.

We recognise that certain groups of patients may find it difficult to access dental care. Community dental services are available to people whose additional needs may mean they are not able to be treated at high street dental practices. Under the Equality Act 2010, health and care organisations, including dental practices, have a legal duty to make reasonable adjustments in their approach and provision to ensure that services are as accessible to disabled patients as they are for everybody else.

As part of our 10-Year Health Plan, integrated care boards (ICBs) will become strategic commissioners with responsibility for using multi-year budgets to enhance local population health while achieving efficiencies. This will help to support the delivery of the three shifts, from hospital to community, from analogue to digital, and from sickness to prevention, that are needed to build a health service fit for the future.

ICBs must continue to deliver their statutory responsibilities and will work with NHS England to ensure this is done effectively within the running costs allowance with savings reinvested in frontline services to deliver better care for patients.

All medicines, including higher-risk ones, are potentially hazardous and should be handled with care during preparation to avoid unnecessary exposure. National Health Service providers are required to follow health and safety legislation and COSHH regulations at all stages.

The Royal Pharmaceutical Society’s guidance, Professional guidance in the safe and secure handling of medicine, includes specific recommendations for the safe preparation of higher-risk medicines. NHS providers are expected to adhere to these standards as part of their statutory and professional obligations under the NHS Standard Contract.

The Care Quality Commission’s (CQC) Medicines Optimisation Quality Statement, along with statements on Safe Environments and Safe and Effective Staffing, also set out requirements for appropriate training, equipment, and policies to ensure staff safety during preparation.

The same principles of safety and regulatory compliance apply during the administration of higher-risk medicines. Staff must follow established protocols to minimise risk and ensure safe handling.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring the safety of medicines and medical devices. When a safety issue is identified, the MHRA communicates with healthcare professionals and stakeholders through channels such as the GOV.UK website, direct emails, and safety alerts, using different methods depending on urgency and impact.

The MHRA’s three-year Strategy for Improving Communications aims to deliver more coordinated, targeted, and effective safety communications to healthcare professionals and patients, supporting safe administration practices.

The CQC’s quality statements also require providers to have appropriate policies and procedures in place to support both patient and staff safety during the administration of medicines.

We continue to monitor the impact of winter pressures on the National Health Service over the winter months.

The Department is continuing to take key steps to ensure the health service is prepared for the colder months. This includes taking actions to try and reduce demand pressure on accident and emergency departments, increasing vaccination rates, and offering health checks to the most vulnerable, as well as stress-testing integrated care boards and trust winter plans to ensure they are able to meet demand and ensure patient flow.

Flu is a recurring pressure that the NHS faces every winter. There is particular risk of severe illness for older people, the very young, pregnant people, and those with certain underlying health conditions. The flu vaccine remains the best form of defense against influenza, particularly for the most vulnerable, and continues to be highly effective at preventing severe disease and hospitalisation.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring the safety of medicines and medical devices, and it continually reviews product safety.

When a safety issue is identified, the MHRA communicates with healthcare professionals and stakeholders through various channels, such as the GOV.UK website, direct emails, and safety alerts, and may use different methods depending on the urgency and impact of the issue.

The MHRA’s three-year Strategy for Improving Communications aims to deliver more coordinated, targeted, and effective safety communications to healthcare professionals and patients using the best available channels.

NHS England has stipulated that all large providers of National Health Services must designate a Medication Safety Officer. They are mandated to implement medication safety within their organisations and are updated regularly on current issues and learning.

NHS England is also reducing risk to staff by increasing the availability of ready to administer products through its Transforming Aseptic Services Programme, with further information available at the following link:

https://www.gov.uk/government/publications/transforming-nhs-pharmacy-aseptic-services-in-england/transforming-nhs-pharmacy-aseptic-services-in-england

The Care Quality Commission’s (CQC) Medicines Optimisation Quality Statement, a copy of which is attached, is focused on ensuring that patients are able to access their medicines safely. The CQC would therefore expect providers to be following their organisations processes and national guidance, where relevant, to ensure that this happens. Organisations providing care need to ensure that staff have the relevant information available to them to keep patients safe through appropriate medicines use, as well as supporting them to undertake their roles safely.

The Department recognises that there are stark inequalities for women and babies, and that they should receive the high-quality care they deserve, regardless of their background, location, or ethnicity. Stillbirth and neonatal mortality rates remain higher for mothers in more deprived areas.

A number of interventions specifically aimed at addressing maternal and neonatal inequalities are underway. These include the Perinatal Equity and Anti-Discrimination Programme, delivery of an inequalities dashboard, and projects on removing racial bias from clinical education and embedding genetic risk equity. Additionally, all local areas have published Equity and Equality action plans to tackle inequalities for women and babies from ethnic minorities and those living in the most deprived areas.

We are putting in place immediate actions to improve safety across maternity and neonatal care, which includes the implementation of the Saving Babies Lives Care Bundle. This bundle is a package of evidence-based interventions to support staff to reduce stillbirth, neonatal brain injury, neonatal death, and pre-term births. It includes guidance on managing multiple pregnancies to ensure optimal care for the woman and baby.

NHS England is also introducing a Maternal Mortality Care Bundle to set clear standards across all services and address the leading causes of maternal mortality. Women from black and Asian backgrounds are more at risk of specific clinical conditions that are the leading causes of death. This bundle will target these conditions, and we expect a decline in deaths and harm.

To further target disparities in maternal care, Baroness Amos is chairing the National Independent Maternity and Neonatal Investigation. The investigation aims to identify the drivers and impact of inequalities faced by women, babies, and families from black and Asian backgrounds, those from deprived groups, and those from other marginalised groups when receiving maternity and neonatal care.

The Government is also setting up a National Maternity and Neonatal Taskforce, chaired by my Rt Hon. Friend, the Secretary of State for Health and Social Care, to address inequalities in maternal and neonatal care and to promote health equity in the delivery of those services.

The Department recognises that there are stark inequalities for women and babies, and that they should receive the high-quality care they deserve, regardless of their background, location, or ethnicity. Stillbirth and neonatal mortality rates remain higher for mothers in more deprived areas.

A number of interventions specifically aimed at addressing maternal and neonatal inequalities are underway. These include the Perinatal Equity and Anti-Discrimination Programme, delivery of an inequalities dashboard, and projects on removing racial bias from clinical education and embedding genetic risk equity. Additionally, all local areas have published Equity and Equality action plans to tackle inequalities for women and babies from ethnic minorities and those living in the most deprived areas.

We are putting in place immediate actions to improve safety across maternity and neonatal care, which includes the implementation of the Saving Babies Lives Care Bundle. This bundle is a package of evidence-based interventions to support staff to reduce stillbirth, neonatal brain injury, neonatal death, and pre-term births. It includes guidance on managing multiple pregnancies to ensure optimal care for the woman and baby.

NHS England is also introducing a Maternal Mortality Care Bundle to set clear standards across all services and address the leading causes of maternal mortality. Women from black and Asian backgrounds are more at risk of specific clinical conditions that are the leading causes of death. This bundle will target these conditions, and we expect a decline in deaths and harm.

To further target disparities in maternal care, Baroness Amos is chairing the National Independent Maternity and Neonatal Investigation. The investigation aims to identify the drivers and impact of inequalities faced by women, babies, and families from black and Asian backgrounds, those from deprived groups, and those from other marginalised groups when receiving maternity and neonatal care.

The Government is also setting up a National Maternity and Neonatal Taskforce, chaired by my Rt Hon. Friend, the Secretary of State for Health and Social Care, to address inequalities in maternal and neonatal care and to promote health equity in the delivery of those services.

The 2025 Autumn Budget confirmed that the Department’s capital budgets will rise to £15.2 billion by the end of the 2025 Spending Review period, in 2029/30, to invest in the National Health Service and wider health infrastructure. The following table shows the planned Capital Departmental Expenditure Limits from 2024/25 to 2029/30:

Funding allocations for national capital programmes for spend in the NHS across the 2025 Spending Review period are outlined in the NHS Capital Planning Guidance, for 2026/27 to 2029/30, at the following link:

https://www.england.nhs.uk/long-read/capital-guidance-2026-27-to-2029-30/

Business planning is conducted each financial year to ensure capital funding is allocated appropriately. Therefore, the allocations set out in the guidance represent indicative figures. The following table shows the allocations set out for the national programme, for estates safety, for reinforced autoclaved aerated concrete work, and for constitutional standards and left shift, from 2025/26 to 2029/30:

In addition, the 2025 Autumn Budget confirmed £300 million of additional capital investment in NHS technology, building on the investment of up to £10 billion of combined revenue and capital by 2028/29 announced at the 2025 Spending Review. We are also investing over £400 million for upgrades to primary care buildings and neighbourhood health centres over the 2026/27 to 2029/30 period.

We remain committed to delivering all schemes within the New Hospital Programme, which will continue through the 2025 Spending Review period, with funding rising from £979 million in 2026/27 to £3 billion by 2029/30.

Our plans fully allocate research and development funding, which is classified as capital, and for agreed national infrastructure and pandemic preparedness schemes.

The Department does not routinely hold back unallocated capital but has an active role in managing the overall position throughout the year as pressures and underspends emerge as part of core financial management, to ensure capital funding is maximised to address strategic priorities and delivery for the taxpayer.

On 20 January 2025, my Rt Hon. Friend, the Secretary of State for Health and Social Care announced a new, realistic plan to deliver the New Hospital Programme (NHP) and we continue to work to these timelines. As set out in the Plan for Implementation, delivery expectations may be subject to change depending on local and national factors and the programme reserves the right to adjust the delivery plan as schemes develop in the future.

We are prioritising the seven hospitals built wholly or primarily from reinforced autoclaved aerated concrete (RAAC), as part of Wave 1, with ongoing mitigations in place to ensure patient and staff safety. Priority will be given to the most affected buildings and services.

My Rt Hon. Friend, the Secretary of State for Health and Social Care has commissioned a comprehensive site-by-site report into these seven hospitals, which will help inform individual development plans, which continue to progress at pace.

£1.6 billion will be provided to continue supporting NHS England’s national RAAC programme across the 2025 Spending Review period. The seven NHP RAAC replacement hospitals continue to receive funding and support from NHS England’s national RAAC programme ahead of the delivery of replacement hospitals.

On 20 January 2025, my Rt Hon. Friend, the Secretary of State for Health and Social Care announced a new, realistic plan to deliver the New Hospital Programme (NHP) and we continue to work to these timelines. As set out in the Plan for Implementation, delivery expectations may be subject to change depending on local and national factors and the programme reserves the right to adjust the delivery plan as schemes develop in the future.

We are prioritising the seven hospitals built wholly or primarily from reinforced autoclaved aerated concrete (RAAC), as part of Wave 1, with ongoing mitigations in place to ensure patient and staff safety. Priority will be given to the most affected buildings and services.

My Rt Hon. Friend, the Secretary of State for Health and Social Care has commissioned a comprehensive site-by-site report into these seven hospitals, which will help inform individual development plans, which continue to progress at pace.

£1.6 billion will be provided to continue supporting NHS England’s national RAAC programme across the 2025 Spending Review period. The seven NHP RAAC replacement hospitals continue to receive funding and support from NHS England’s national RAAC programme ahead of the delivery of replacement hospitals.

On 20 January 2025, my Rt Hon. Friend, the Secretary of State for Health and Social Care announced a new, realistic plan to deliver the New Hospital Programme (NHP) and we continue to work to these timelines. As set out in the Plan for Implementation, delivery expectations may be subject to change depending on local and national factors and the programme reserves the right to adjust the delivery plan as schemes develop in the future.

We are prioritising the seven hospitals built wholly or primarily from reinforced autoclaved aerated concrete (RAAC), as part of Wave 1, with ongoing mitigations in place to ensure patient and staff safety. Priority will be given to the most affected buildings and services.

My Rt Hon. Friend, the Secretary of State for Health and Social Care has commissioned a comprehensive site-by-site report into these seven hospitals, which will help inform individual development plans, which continue to progress at pace.

£1.6 billion will be provided to continue supporting NHS England’s national RAAC programme across the 2025 Spending Review period. The seven NHP RAAC replacement hospitals continue to receive funding and support from NHS England’s national RAAC programme ahead of the delivery of replacement hospitals.

No assessment has been made centrally of the potential impact on in-patients of charging in hospitals for television, WiFi, and telephone services.

National Health Service providers are locally responsible for the provision of bedside television and similar services, including the charges for them. If patients do not wish to or are unable to afford the cost of the bedside television, they should still be able to watch the free to view television via their own devices and local hospital Wi-Fi, or in the hospital day rooms or communal areas.

The Department and NHS England have been working together to announce a series of measures to tackle antisemitism and racism across the National Health Service, which includes the introduction of mandatory antisemitism and anti-racism training for all NHS staff.

In terms of unconscious bias training, there is no national NHS-wide policy on this training in the NHS. Individual NHS organisations have responsibility for training their own staff and provide relevant training where appropriate.

As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board is overseeing the development of a new series of service frameworks to accelerate progress in conditions where there is potential for rapid and significant improvements in quality of care and productivity.

Early priorities include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions with significant health and economic impacts for future waves of modern service frameworks.

The Government recognises the challenges faced by women with endometriosis and the impact it has on their lives, their relationships, and their participation in education and the workforce.

In November 2024, the National Institute for Health and Care Excellence (NICE) updated their guideline on endometriosis to makes firmer recommendations for healthcare professionals on referral and investigations for women with a suspected diagnosis and will help the estimated one in ten women with endometriosis to receive a diagnosis faster. Over the next year, NICE will be working with National Health Service systems to ensure adoption of this best practice endometriosis care, including access to approved medicines.

Through the National Institute for Health and Care Research (NIHR), we have commissioned a number of studies focused on endometriosis diagnosis, treatment, and patient experience. At present, the NIHR is funding six research awards totalling an investment of approximately £5.8 million.

Alongside the updated guidelines and research investment, two new treatments have been approved, and we are taking action to cut gynaecology waiting lists through our Elective Reform Plan.

But we know there is more to do. That is why we are renewing the Women’s Health Strategy, to update on delivery and set out how the Government is taking further steps to improve women’s health as we deliver the 10-Year Health Plan. It will also address gaps from the 2022 strategy and drive further changes on enduring challenges such as creating a system that listens to women, and tackling health inequalities.